Browsing Tag
Biocon Biologics
24 posts
Viatris (Nasdaq: VTRS) exits Biocon Biologics with $815m deal as biosimilars reentry accelerates
Viatris unlocks $815M from Biocon Biologics exit and regains biosimilars access. Find out how this reshapes its 2026 global pharma strategy.
How Canada became the preferred launchpad for ophthalmic biosimilars in 2025
With Yesafili’s approval, Canada is emerging as the global launchpad for ophthalmic biosimilars. Explore what’s driving this strategic shift.
Biocon (NSE: BIOCON) gains EU nod for Denosumab biosimilars Vevzuo and Evfraxy to target bone health market
Biocon Biologics receives EU approval for Denosumab biosimilars Vevzuo and Evfraxy. Find out how this milestone could reshape its European biosimilars strategy.
Can Indian biosimilar makers dominate ophthalmology markets after Eylea patent expiries?
With Eylea patents expiring, Indian biosimilar makers are eyeing global ophthalmology markets. Find out who’s leading and what’s next.
Biocon Biologics gets Health Canada approval for Yesafili aflibercept biosimilar
Biocon Biologics wins Health Canada approval for Yesafili, its 10th biosimilar. Find out how this launch could reshape retinal care access in Canada.
Can Dr. Reddy’s build a biosimilars portfolio that rivals Biocon and global MNCs in regulated markets?
Explore Dr. Reddy’s biosimilars pipeline, regulatory milestones, and commercial strategy—can it compete with Biocon and global pharma giants in 2025?
Can Biocon Biologics lead biosimilar disruption in ophthalmology with Yesafili?
Biocon Biologics secures 2026 U.S. launch for Yesafili, its interchangeable biosimilar to Eylea. Find out how this reshapes eye care access and competition.
Biocon Biologics strengthens US market presence with Civica insulin deal
As insulin prices remain a pressing concern in the United States, Biocon Biologics collaboration with Civica, Inc. has…
Biocon reports Q2FY25 revenue of Rs 3,623cr amid generics pressure
Biocon Limited, a leading global biopharmaceutical company, released its consolidated financial results for Q2FY25, reporting a total revenue…
Eris Lifesciences acquires Biocon Biologics’ branded formulation business for Rs 1,242cr
In a strategic move that reshapes the landscape of India’s injectables market, Eris Lifesciences Ltd., a leading player…